97
Participants
Start Date
December 31, 2014
Primary Completion Date
July 31, 2019
Study Completion Date
October 31, 2019
BBI608
BBI608 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
BBI503
BBI503 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
Sorafenib
Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.
USOR - New York Oncology Hematology, Albany
University of Rochester, Wilmot Cancer Institute, Rochester
Drexel University, Philadelphia
Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Roanoke
Wake Forest Baptist Health, Winston-Salem
Carolinas Health Care System, Charlotte
Piedmont Cancer Institute, P.C., Atlanta
Winship Cancer Institute of Emory University, Atlanta
Baptist Health Medical Group Oncology, LLC, Miami
Norton Cancer Institute, Louisville
University of Cincinnati, Vontz Center, Cincinnati
Karmanos Cancer Institute, Detroit
Minnesota Oncology Hematology, P.A., Minneapolis
Kansas City Research Institure, Kansas City
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
USOR - Texas Oncology, Tyler, Tyler
USOR - Texas Oncology, Fort Worth 12th Ave, Fort Worth
Oncology Consultants, Houston
Texas Oncology-McAllen South Second Street, McAllen
USOR - Texas Oncology, Austin Midtown, Austin
Texas Oncology - El Paso Cancer Treatment Center Joe Battle, El Paso
USOR - Rocky Mountain Cancer Centers, Denver
Mayo Clinic, Phoenix
Banner MD Anderson Cancer Center, Gilbert
USOR - Comprehensive Cancer Centers of Nevada, Las Vegas
USC Norris Comprehensive Cancer Center, Los Angeles
California Center Associates for Research and Excellence, Inc. (Ccare), Encinitas
Southern California Research Center, Coronado
The Valley Hospital Luckow Pavilion, Paramus
Sumitomo Pharma America, Inc.
INDUSTRY